 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
43 News |  |
- || Cationorm / Yissum Research Development Company, Santen
Trial completion date, Trial primary completion date, Head-to-Head: PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - Apr 19, 2024
P=N/A, N=80, Recruiting, Sponsor: Santen SAS
Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Dec 2024
- || Cationorm / Yissum Research Development Company, Santen
Trial completion date, Trial primary completion date, Head-to-Head: PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - May 16, 2023
P=N/A, N=80, Recruiting, Sponsor: Santen SAS
Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Dec 2024 Trial completion date: Feb 2023 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
- | Vekacia (ciclosporin ophthalmic) / Santen, Cationorm / Yissum Research Development Company, Santen
Trial completion, Surgery: CSA2020: Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery (clinicaltrials.gov) - Feb 14, 2023
P1, N=101, Completed, Sponsor: Campus Bio-Medico University
Trial completion date: Feb 2023 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023 Active, not recruiting --> Completed
- ||| Cationorm / Yissum Research Development Company, Santen
Enrollment open, Trial completion date, Trial primary completion date, Head-to-Head: PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - May 20, 2022
P=N/A, N=80, Recruiting, Sponsor: Santen SAS
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial completion date: Nov 2022 --> Feb 2023 | Trial primary completion date: Apr 2022 --> Oct 2022
- | Cationorm / Yissum Research Development Company, Santen
Trial completion date, Trial primary completion date: Effect of Lipid Based Eye Drops on Tear Film Lipid Layer Thickness (clinicaltrials.gov) - Apr 7, 2022
P=N/A, N=40, Recruiting, Sponsor: Medical University of Vienna
Not yet recruiting --> Recruiting | Trial completion date: Nov 2022 --> Feb 2023 | Trial primary completion date: Apr 2022 --> Oct 2022 Trial completion date: Sep 2021 --> Sep 2023 | Trial primary completion date: Sep 2021 --> Sep 2023
- | Vekacia (ciclosporin ophthalmic) / Santen, Cationorm / Yissum Research Development Company, Santen
Enrollment closed, Trial completion date, Surgery: CSA2020: Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery (clinicaltrials.gov) - Jan 6, 2022
P1, N=101, Active, not recruiting, Sponsor: Campus Bio-Medico University
Trial completion date: Sep 2021 --> Sep 2023 | Trial primary completion date: Sep 2021 --> Sep 2023 Recruiting --> Active, not recruiting | Trial completion date: Oct 2021 --> Feb 2022
- || Cationorm / Yissum Research Development Company, Santen
Trial initiation date, Head-to-Head: PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - Sep 21, 2021
P=N/A, N=80, Not yet recruiting, Sponsor: Santen SAS
Recruiting --> Active, not recruiting | Trial completion date: Oct 2021 --> Feb 2022 Initiation date: Jun 2021 --> Sep 2021
- | Cationorm / Yissum Research Development Company, Santen
Preclinical, Journal: High-Frequency Application of Cationic Agents Containing Lubricant Eye Drops Causes Cumulative Corneal Toxicity in an Ex Vivo Eye Irritation Test Model. (Pubmed Central) - Sep 17, 2021
The consistency of these predictions was previously demonstrated by the EVEIT for BAC, phosphate buffer, and others. The EVEIT is suited for a chronic application prediction of tolerability and toxic side effects of eye drops in particular, and other chemicals in general.
- | Cationorm / Yissum Research Development Company, Santen
Trial completion date, Trial primary completion date: Effect of Lipid Based Eye Drops on Tear Film Lipid Layer Thickness (clinicaltrials.gov) - Sep 8, 2021
P=N/A, N=40, Recruiting, Sponsor: Medical University of Vienna
The EVEIT is suited for a chronic application prediction of tolerability and toxic side effects of eye drops in particular, and other chemicals in general. Trial completion date: Dec 2020 --> Sep 2021 | Trial primary completion date: Dec 2020 --> Sep 2021
- || Cationorm / Yissum Research Development Company, Santen
Trial completion date, Trial primary completion date, Head-to-Head: PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - Jun 18, 2021
P=N/A, N=80, Not yet recruiting, Sponsor: Santen SAS
Trial completion date: Dec 2020 --> Sep 2021 | Trial primary completion date: Dec 2020 --> Sep 2021 Trial completion date: Dec 2021 --> Nov 2022 | Trial primary completion date: Dec 2021 --> Mar 2022
- || Cationorm / Yissum Research Development Company, Santen
Trial initiation date, Head-to-Head: PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - May 19, 2021
P=N/A, N=80, Not yet recruiting, Sponsor: Santen SAS
Trial completion date: Dec 2021 --> Nov 2022 | Trial primary completion date: Dec 2021 --> Mar 2022 Initiation date: Mar 2021 --> Jun 2021
- | Vekacia (ciclosporin ophthalmic) / Santen, Cationorm / Yissum Research Development Company, Santen
New P1 trial, Surgery: CSA2020: Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery (clinicaltrials.gov) - Mar 23, 2021
P1, N=100, Recruiting, Sponsor: Campus Bio-Medico University
- ||| Cationorm / Yissum Research Development Company, Santen
New trial, Head-to-Head: PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - Jan 7, 2021
P=N/A, N=80, Not yet recruiting, Sponsor: Santen SAS
- | Cationorm / Yissum Research Development Company, Santen
Journal: Short-Term Changes in Tear Lipid Layer Thickness After Instillation of Lipid Containing Eye Drops. (Pubmed Central) - Aug 30, 2020
Our results showed that participants' initial LLT affected their responsiveness to lipid-containing eye drops more than other factors. Doctors may choose to measure the baseline LLT of patients before deciding whether to prescribe lipid eye drops to patients.
- || Cationorm / Yissum Research Development Company, Santen
Clinical, Journal: Efficacy and Safety of VisuEvo and Cationorm for the Treatment of Evaporative and Non-Evaporative Dry Eye Disease: A Multicenter, Double-Blind, Cross-Over, Randomized Clinical Trial. (Pubmed Central) - Jul 3, 2020
P=N/A
VSE was non-inferior to CTN in restoring tear film composition, increasing its stability and reducing ocular surface damage in evaporative and non-evaporative DED patients. NCT03833882.
- | Vismed (sodium hyaluronate) / TRB Chemedica, Cationorm / Yissum Research Development Company, Santen
Clinical, Journal: Safety and Tolerability of Overdosed Artificial Tears by Abraded Rabbit Corneas. (Pubmed Central) - Jun 15, 2020
The different ATs were demonstrated to be well tolerated by abraded corneas in vivo, and the extreme overdosing regimen did not hamper the wound healing process of the rabbit eye in comparison to saline. These data did not confirm the ones obtained with the nonvalidated ex vivo eye irritation test.
- Cationorm / Yissum Research Development Company, Santen
Enrollment change, Trial completion date, Trial termination: REMOGEN (clinicaltrials.gov) - Apr 19, 2020
P=N/A, N=26, Terminated, Sponsor: TRB Chemedica
These data did not confirm the ones obtained with the nonvalidated ex vivo eye irritation test. N=96 --> 26 | Trial completion date: Dec 2019 --> Jun 2019 | Recruiting --> Terminated; low recruitment rate
- | Cationorm / Yissum Research Development Company, Santen
Trial completion date, Trial primary completion date: Effect of Lipid Based Eye Drops on Tear Film Lipid Layer Thickness (clinicaltrials.gov) - Feb 23, 2020
P=N/A, N=40, Recruiting, Sponsor: Medical University of Vienna
N=96 --> 26 | Trial completion date: Dec 2019 --> Jun 2019 | Recruiting --> Terminated; low recruitment rate Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Aug 2019 --> Dec 2020
- | Cationorm / Yissum Research Development Company, Santen
Journal: Polishing of Bowman's membrane with diamond burr in the treatment of recurrent corneal erosion syndrome (Pubmed Central) - Aug 15, 2019
Conservative treatment of RCES rarely yields results. Removal of inadequate epithelium and following DBPBM using our original method is a highly effective and accessible procedure for RCES treatment with low risk of complications and relapse.
- | Cationorm / Yissum Research Development Company, Santen
Trial completion: Evaluation of MAF-1217 in Patients With DED (clinicaltrials.gov) - Jul 15, 2019
P=N/A, N=72, Completed, Sponsor: VISUfarma SpA
Removal of inadequate epithelium and following DBPBM using our original method is a highly effective and accessible procedure for RCES treatment with low risk of complications and relapse. Recruiting --> Completed
- || Cationorm / Yissum Research Development Company, Santen
Trial completion date, Trial primary completion date: REMOGEN (clinicaltrials.gov) - Apr 10, 2019
P=N/A, N=96, Recruiting, Sponsor: TRB Chemedica
Recruiting --> Completed Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Cationorm / Yissum Research Development Company, Santen
New trial: Evaluation of MAF-1217 in Patients With DED (clinicaltrials.gov) - Feb 6, 2019
P=N/A, N=72, Recruiting, Sponsor: VISUfarma SpA
- ||| Cationorm / Yissum Research Development Company, Santen
Enrollment open: REMOGEN (clinicaltrials.gov) - Sep 13, 2018
P=N/A, N=96, Recruiting, Sponsor: TRB Chemedica
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Not yet recruiting --> Recruiting
- ||| Cationorm / Yissum Research Development Company, Santen
New trial: REMOGEN (clinicaltrials.gov) - Mar 9, 2018
P=N/A, N=96, Not yet recruiting, Sponsor: TRB Chemedica
- | Cationorm / Yissum Research Development Company, Santen
New trial: Effect of Lipid Based Eye Drops on Tear Film Lipid Layer Thickness (clinicaltrials.gov) - Jan 16, 2018
P=N/A, N=40, Recruiting, Sponsor: Medical University of Vienna